Kristen L Lozada
Overview
Explore the profile of Kristen L Lozada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yori J, Lozada K, Seachrist D, Mosley J, Abdul-Karim F, Booth C, et al.
Cancer Res
. 2014 Jul;
74(17):4762-71.
PMID: 25023728
Resistance to receptor tyrosine kinase (RTK) blockade in breast cancer is often mediated by activation of bypass pathways that sustain growth. Src and mammalian target of rapamycin (mTOR) are two...
2.
Yori J, Seachrist D, Johnson E, Lozada K, Abdul-Karim F, Chodosh L, et al.
Neoplasia
. 2011 Jul;
13(7):601-10.
PMID: 21750654
Krüppel-like factor 4 (KLF4) is a zinc finger transcription factor that functions as an oncogene or tumor suppressor in a highly tissue-specific cell-dependent manner. However, its precise role in breast...
3.
Montanez-Wiscovich M, Shelton M, Seachrist D, Lozada K, Johnson E, Miedler J, et al.
J Pathol
. 2010 Sep;
222(3):271-81.
PMID: 20814902
The LIM-only protein, LMO4, is a transcriptional modulator overexpressed in breast cancer. It is oncogenic in murine mammary epithelium and is required for G2/M progression of ErbB2-dependent cells as well...
4.
Johnson E, Seachrist D, DeLeon-Rodriguez C, Lozada K, Miedler J, Abdul-Karim F, et al.
J Biol Chem
. 2010 Jul;
285(38):29491-501.
PMID: 20595387
Breast cancers that overexpress the receptor tyrosine kinase ErbB2/HER2/Neu result in poor patient outcome because of extensive metastatic progression. Herein, we delineate a molecular mechanism that may govern this malignant...
5.
Bernardo G, Lozada K, Miedler J, Harburg G, Hewitt S, Mosley J, et al.
Development
. 2010 May;
137(12):2045-54.
PMID: 20501593
FOXA1, estrogen receptor alpha (ERalpha) and GATA3 independently predict favorable outcome in breast cancer patients, and their expression correlates with a differentiated, luminal tumor subtype. As transcription factors, each functions...